Effect of Lu177-dotatate in meningioma

Phase 2

• Conditions: Meningioma.; Malignant neoplasm of meninges, unspecified; C70.9

• Registration Number: IRCT20190623043986N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Pathologically-proved case of meningioma
Radiologic evidence of recurrence after at least two surgeries with no response to other standard therapies
Sufficient radiotracer uptake in the Tc99m-octreotide scan
Hemoglobulin (HB)>8 g/dl
White blood cell count (WBC) > 2500 /mm3
platelet count>70000 /mm3
Glomerular filtration rate (GFR) > 50ml/min
Consent to participate in the study
Life expectancy more than 6 months

Exclusion Criteria

Pregnancy or lactation
Being candidate for other therapeutic measures
Development of unpredictable complications or other limiting or severe diseases
Severe hematologic complications
Severe renal complications

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in tumor size based on MRI findings. Timepoint: Before and during 3-6 months after therapy. Method of measurement: Brain MRI.;Change in radiotracer tumoral uptake based on Tc99m-octreotide scan. Timepoint: Before and during 3-6 months after therapy. Method of measurement: Tc99m-ocreotide scan.;Hematologic toxicity. Timepoint: 4-5 weeks after each cycle. Method of measurement: Complete blood count (CBC).;Renal toxicity. Timepoint: 4-5 weeks after each cycle. Method of measurement: Measurement of creatinine by laboratory test.